Alpelisib, an α-selective phosphatidylinositol 3-kinase (PI3K) inhibitor, plays a crucial role in insulin signaling, and has been used in patients with refractory congenital hyperinsulinism and non-islet cell tumor hypoglycemia (47, 48). Here, INS is linked to pancreatic neuroendocrine tumor.